Paul A. Bethel

Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor

M. Raymond V. Finlay, Mark J. Anderton, Susan Ashton et al. · Journal of Medicinal Chemistry · 2014 · 602 citations · Full text

Medicine, Oncology, Pharmacology +15

Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR)

Richard A. Ward, Mark J. Anderton, Susan Ashton et al. · Journal of Medicinal Chemistry · 2013 · 261 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Discovery of a Potent and Selective Oral Inhibitor of ERK1/2 (AZD0364) That Is Efficacious in Both Monotherapy and Combination Therapy in Models of Nonsmall Cell Lung Cancer (NSCLC)

Richard A. Ward, Mark J. Anderton, Paul A. Bethel et al. · Journal of Medicinal Chemistry · 2019 · 78 citations · Full text

Medicine, Oncology, Pharmacology +17

Structure-Guided Discovery of Potent and Selective Inhibitors of ERK1/2 from a Modestly Active and Promiscuous Chemical Start Point

Richard A. Ward, Paul A. Bethel, Calum Cook et al. · Journal of Medicinal Chemistry · 2017 · 52 citations · Full text

Pharmacy, Medicinal Chemistry, Oncology +16

Reactions of organotin tetrazoles: synthesis of functionalised poly-tetrazoles

Paul A. Bethel, Michael S. Hill, Mary F. Mahon et al. · Journal of the Chemical Society Perkin Transactions 1 · 1999 · 45 citations

Natural Sciences, Chemistry, Bioorganic Chemistry +12